Hypersomnia Clinical Trials, Pipeline Insight, FDA Approvals 2023 | Key Companies- Takeda, Axsome Therapeutics, KemPharm, Orexia Therapeutics, Pfizer, Eisai, and Others

DelveInsight's, "Hypersomnia Pipeline Insight 2023" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Hypersomnia pipeline landscape. It covers the Hypersomnia pipeline drug profiles, including Hypersomnia clinical trials and nonclinical stage products. It also covers the Hypersomnia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Recent Developmental Activities in the Hypersomnia Treatment Landscape

• In October 2021, Schrödinger and Centessa Pharmaceuticals together with subsidiary Orexia Therapeutics announced an exclusive collaboration focused on the discovery of novel therapeutics targeting the orexin-2 receptor (OX2R), which is known to play a role in a broad spectrum of sleep disorders, including narcolepsy. The collaboration provides Orexia with substantial access to Schrödinger's entire computational platform as well as Schrödinger's extensive expertise in ultra-large-scale deployment of its technology.

• In April 2021, KemPharm announced the submission of an Investigational New Drug (IND) application seeking authorization from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial evaluating KP1077 as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder. Upon IND clearance, KemPharm anticipates initiating KP1077 Phase 2 IH trial as early as the second half of 2022.

To explore more information on the latest breakthroughs in the Hypersomnia Pipeline treatment landscape of the report, click here @ Hypersomnia Pipeline Outlook- https://www.delveinsight.com/sample-request/hypersomnia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hypersomnia Overview
Hypersomnia, a complaint of excessive daytime sleep or sleepiness, affects 4% to 6% of the population, with an impact on the everyday life of the patient. The obvious main symptom of hypersomnia Is a constant complaint of excessive daytime sleep or sleepiness, which affects the everyday life of the patient.

Key Takeaways from the Hypersomnia Pipeline Report

• DelveInsight's Hypersomnia pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Hypersomnia treatment.

• The leading Hypersomnia Companies include Bioprojet, Balance Therapeutics, Gate Neurosciences, NLS Pharmaceutics, Takeda, Axsome Therapeutics, KemPharm, Orexia Therapeutics, Pfizer, Eisai, Jazz Pharmaceuticals, Cephalon, Teva Pharmaceuticals, and others

• Promising Hypersomnia Pipeline Therapies include TAK-861, Modafinil, armodafinil, Solriamfetol Oral Tablet, JZP-258, and others

• The Hypersomnia companies and academics are working to assess challenges and seek opportunities that could influence in Hypersomnia R&D. The Hypersomnia therapies under development are focused on novel approaches to treat/improve in Hypersomnia.

Request a sample and discover the recent advances in Hypersomnia Ongoing Clinical Trial Analysis and Medications, click here @ Hypersomnia Treatment Landscape- https://www.delveinsight.com/sample-request/hypersomnia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Hypersomnia Emerging Drugs Profile

• Reboxetine: Axsome Therapeutics
Reboxetine is a highly selective and potent norepinephrine reuptake inhibitor being developed for the treatment of narcolepsy. It is thought to modulate noradrenergic activity to promote wakefulness, maintain muscle tone and enhance cognition. Reboxetine has an extensive safety record in Europe and in over 40 countries where it's approved for the treatment of depression. In narcolepsy, AXS-12 is supported by positive pre-clinical and Phase 2 clinical results. AXS-12 is an investigational drug not approved by the FDA and its safety and effectiveness have not been established.

• Quilience: NLS Pharmaceutics
Quilience, is a proprietary extended-release formulation of mazindol (mazindol ER) and is being developed for the treatment of narcolepsy, and potentially other sleep-wake disorders such as idiopathic hypersomnia. Quilience in adult subjects suffering from narcolepsy is currently ongoing in the United States.

Hypersomnia Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Hypersomnia. The companies which have their Hypersomnia drug candidates in the most advanced stage, i.e. Phase III include, Axsome Therapeutics.

For further information, refer to the detailed Hypersomnia Unmet Needs, Hypersomnia Market Drivers, and Barriers, click here for Hypersomnia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/hypersomnia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Hypersomnia Pipeline Report

• Coverage- Global

• Hypersomnia Companies- Bioprojet, Balance Therapeutics, Gate Neurosciences, NLS Pharmaceutics, Takeda, Axsome Therapeutics, KemPharm, Orexia Therapeutics, Pfizer, Eisai, Jazz Pharmaceuticals, Cephalon, Teva Pharmaceuticals, and others

• Hypersomnia Pipeline Therapies- TAK-861, Modafinil, armodafinil, Solriamfetol Oral Tablet, JZP-258, and others

• Hypersomnia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Hypersomnia Market Drivers and Hypersomnia Market Barriers, click here @ Hypersomnia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/hypersomnia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Hypersomnia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hypersomnia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Reboxetine: Axsome Therapeutics
9. Drug profiles in the detailed report…..
10. Early Stage Products (Phase II)
11. KP 1077: KemPharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. GATE-101: NLS Pharmaceutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Hypersomnia Key Companies
21. Hypersomnia Key Products
22. Hypersomnia- Unmet Needs
23. Hypersomnia- Market Drivers and Barriers
24. Hypersomnia- Future Perspectives and Conclusion
25. Hypersomnia Analyst Views
26. Hypersomnia Key Companies
27. Appendix

Got Queries? Find out the related information on Hypersomnia Mergers and acquisitions, Hypersomnia licensing activities @ Hypersomnia Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/hypersomnia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91 9568243403
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.